Patents by Inventor Ruichao Shen

Ruichao Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoxazole analogs as FXR agonists and methods of use thereof
    Patent number: 10450306
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: October 22, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jun Ma, Guoqiang Wang, Bin Wang, Xuechao Xing, Ruichao Shen, Jing He, Yat Sun Or
  • ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20190248777
    Abstract: The present invention provides compounds of Formula (I): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
    Type: Application
    Filed: February 11, 2019
    Publication date: August 15, 2019
    Inventors: Ruichao Shen, Jun Ma, Guoqiang Wang, Xuechao Xing, Yat Sun Or
  • Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10364267
    Abstract: The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: July 30, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yat Sun Or, Jiang Long, Guoyou Xu, Peng Dai, Ruichao Shen, Xuechao Xing, Jing He
  • ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20190194216
    Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Application
    Filed: December 12, 2018
    Publication date: June 27, 2019
    Inventors: Yat Sun Or, Jun Ma, Guoqiang Wang, Xuechao Xing, Ruichao Shen, Bin Wang
  • BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20190194245
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 27, 2019
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Jiang Long, Peng Dai, Xuechao Xing, Jing He
  • Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10323060
    Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: June 18, 2019
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yat Sun Or, Xuechao Xing, Guoqiang Wang, Ruichao Shen, Jing He
  • Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10266560
    Abstract: The present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: April 23, 2019
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yat Sun Or, Guoqiang Wang, Ruichao Shen, Xuechao Xing
  • Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 10253018
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 9, 2019
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Guoqiang Wang, Brett Granger, Ruichao Shen, Yong He, Xuechao Xing, Jun Ma, Jiang Long, Jing He, Bin Wang, Yat Sun Or
  • Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10246483
    Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: April 2, 2019
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Ruichao Shen, Yat Sun Or, Guoqiang Wang
  • Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 10246439
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 2, 2019
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Brett Granger, Guoqiang Wang, Ruichao Shen, Jun Ma, Xuechao Xing, Jing He, Yong He, Jiang Long, Bin Wang, Yat Sun Or
  • TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20190062310
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Application
    Filed: August 27, 2018
    Publication date: February 28, 2019
    Inventors: Guoqiang Wang, Jing He, Bin Wang, Ruichao Shen, Brett Granger, Yat Sun Or
  • Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
    Patent number: 10208081
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: February 19, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Jiang Long, Peng Dai, Xuechao Xing, Jing He
  • Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof
    Publication number: 20180362501
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Application
    Filed: May 24, 2018
    Publication date: December 20, 2018
    Inventors: Guoqiang Wang, Brett Granger, Ruichao Shen, Yong He, Xuechao Xing, Jun Ma, Jiang Long, Jing He, Bin Wang, Yat Sun Or
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20180362502
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Application
    Filed: May 24, 2018
    Publication date: December 20, 2018
    Inventors: Brett Granger, Guoqiang Wang, Ruichao Shen, Jun Ma, Xuechao Xing, Jing He, Yong He, Jiang Long, Bin Wang, Yat Sun Or
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20180362503
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Application
    Filed: May 24, 2018
    Publication date: December 20, 2018
    Inventors: Brett Granger, Guoqiang Wang, Ruichao Shen, Jing He, Yong He, Xuechao Xing, Jun Ma, Jiang Long, Bin Wang, Yat Sun Or
  • Isoxazole derivatives as FXR agonists and methods of use thereof
    Patent number: 10149835
    Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: December 11, 2018
    Assignee: Elmore Patent Law Group, P.C.
    Inventors: Yat Sun Or, Xuechao Xing, Ruichao Shen, Bin Wang, Brett Granger, Jun Ma, Jing He, Jiang Long, Yong He, Guoqiang Wang
  • Isoxazole analogs as FXR agonists and methods of use thereof
    Patent number: 10144729
    Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: December 4, 2018
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yat Sun Or, Jun Ma, Bin Wang, Yong He, Xuechao Xing, Ruichao Shen, Brett Granger, Jing He, Jiang Long, Guoqiang Wang
  • Isoxazole derivatives as FXR agonists and methods of use therof
    Patent number: 10138228
    Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: November 27, 2018
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yat Sun Or, Yong He, Ruichao Shen, Xuechao Xing, Brett Granger, Bin Wang, Jun Ma, Jing He, Jiang Long, Guoqiang Wang
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20180327388
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Application
    Filed: May 14, 2018
    Publication date: November 15, 2018
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • Isoxazole derivatives as FXR agonists and methods of use thereof
    Patent number: 10080742
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: September 25, 2018
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Ruichao Shen, Xuechao Xing, Brett Granger, Bin Wang, Jun Ma, Jing He, Yong He, Jiang Long, Guoqiang Wang